Antipsychotic Trials Biased Towards Sponsor’s Drug, Study Suggests
Executive Summary
Clinical trial protocols for head-to-head comparisons of antipsychotic drugs should be reviewed by regulatory authorities like FDA to eliminate potential sources of bias, according to a recent analysis published in the American Journal of Psychiatry